Pd09-04 interim analysis of a phase i single-arm study of the combination of durvalumab (medi4736) and vicinium (oportuzumab monatox, vb4-845) in subjects with high-grade non-muscle-invasive bladder cancer previously treated with bacillus calmette-guerin (bcg) (nct03258593)